MedTrace Logo

Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer

NCT00089999 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2017-02-28

Study results available
· View outcomes & findings →

Summary

This phase II study will evaluate and compare the efficacy and tolerability of two dose schedules (1500 mg QD and 500 mg BID) of oral Lapatinib as treatment for patients with advanced or metastatic breast cancer.

Conditions

  • Neoplasms, Breast

Interventions

DRUG

Lapatinib

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States
  • Chile
  • Hong Kong
  • India
  • Malaysia
  • Mexico
  • Pakistan
  • Peru
  • Poland
  • Singapore
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00089999 on ClinicalTrials.gov